Home › NDC Lookup › RxCUI directory › RxCUI 2585460

24 HR amphetamine 10 MG Extended Release Oral Tablet — RxCUI 2585460

RxNorm drug concept · Semantic clinical drug
RxCUI 2585460 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2585460
Official name24 HR amphetamine 10 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asamphetamine 10 MG 24HR Extended Release Oral Tablet
FDA products mapped5
Package NDCs mapped6
Reported Medicaid activity (SDUD)71,287 prescriptions · 40 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Amphetamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It depends on the specific product. Most amphetamine products — including Adzenys XR-ODT, Dyanavel XR, and the extended-release orally disintegrating tablets — are approved to trea...
  • What conditions is amphetamine actually approved to treat?
  • You can take most amphetamine products with or without food — it won't meaningfully change how much you absorb. That said, eating (especially a high-fat meal) can delay when it kic...
  • Is it okay to take this with food, or does it have to be on an empty stomach?
📖 Read our full Amphetamine guide →

🕸️ Concept Web — How 24 HR amphetamine 10 MG Extended Release Oral Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR amphetamine 10 MG Extended Release Oral Tablet RxCUI 2585460

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Amphetamine 725
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Dyanavel 1720587
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Amphetamine Extended Release Oral Tablet 1739802
    • Amphetamine Oral Product 1152906
    • Amphetamine Pill 1152907
    • Amphetamine Extended Release Oral Tablet [Dyanavel] 2585458
    • Dyanavel Oral Product 1720591
    • Dyanavel Pill 2585457
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Amphetamine 10 MG SCDC · 2585454
  • Amphetamine Extended Release Oral Tablet SCDF · 1739802
  • Amphetamine Oral Product SCDG · 1152906
  • Amphetamine Pill SCDG · 1152907

Brand-Name Concepts

📦 FDA Products & Package NDCs

5 products · 6 package NDCs
6 package NDCs map to RxCUI 2585460 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24478-0102-01 1 BOTTLE in 1 CARTON (24478-102-01) / 464 mL in 1 BOTTLE Dyanavel XR NextWave Pharmaceuticals, Inc 2022-07-25
24478-0102-02 1 BOTTLE in 1 CARTON (24478-102-02) / 60 mL in 1 BOTTLE Dyanavel XR NextWave Pharmaceuticals, Inc 2026-03-30
24478-0106-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (24478-106-01) DYANAVEL XR NextWave Pharmaceuticals, Inc 2022-08-01
24478-0108-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (24478-108-01) DYANAVEL XR NextWave Pharmaceuticals, Inc 2022-08-01
24478-0109-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (24478-109-01) DYANAVEL XR NextWave Pharmaceuticals, Inc 2022-08-01
24478-0110-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (24478-110-01) DYANAVEL XR NextWave Pharmaceuticals, Inc 2022-08-01
Observed labelers: NextWave Pharmaceuticals, Inc (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.